Syon Capital LLC Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Syon Capital LLC acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,112 shares of the biotechnology company's stock, valued at approximately $500,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Sarepta Therapeutics by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock valued at $75,842,000 after acquiring an additional 12,000 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $3,829,000. Nordea Investment Management AB increased its position in shares of Sarepta Therapeutics by 19.1% during the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after buying an additional 10,815 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Sarepta Therapeutics by 16,717.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after buying an additional 84,926 shares during the period. Finally, Van ECK Associates Corp increased its position in shares of Sarepta Therapeutics by 24.4% during the fourth quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company's stock worth $10,315,000 after buying an additional 16,658 shares during the period. Institutional investors own 86.68% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on SRPT. Morgan Stanley decreased their price objective on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research report on Friday, April 11th. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. HC Wainwright reiterated a "neutral" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Needham & Company LLC decreased their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research report on Thursday, April 3rd. Finally, Royal Bank of Canada cut shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their price target for the stock from $161.00 to $87.00 in a report on Monday, March 31st. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $158.70.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company's stock.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded up $1.07 on Monday, hitting $61.51. 1,155,716 shares of the stock traded hands, compared to its average volume of 1,424,018. The business's fifty day moving average is $77.32 and its two-hundred day moving average is $105.59. Sarepta Therapeutics, Inc. has a 12 month low of $48.01 and a 12 month high of $173.25. The firm has a market capitalization of $5.97 billion, a price-to-earnings ratio of 49.21 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.